BioBridgeX
Log inCompare quotes
Indication

Cardiovascular CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a cardiovascular program means sourcing CRO and CDMO partners for cardiac-specific in vivo models (heart failure, atherosclerosis, arrhythmia, thrombosis), telemetry and hERG cardiac-safety work, DMPK, cardiac imaging core labs, ECG and biomarker analysis, and large outcomes-trial operations. BioBridgeX is a neutral marketplace: free for buyers, a flat 2% supplier fee, and you compare quotes and contract directly with your chosen suppliers.

Cardiovascular CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Cardiovascular CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does a Cardiovascular program need?

Cardiovascular covers a wide spread of biology, and the outsourcing you need bends hard to which corner you are in. A heart failure program leans on different models and endpoints than an antithrombotic, an antihypertensive, a lipid-lowering agent, a PAH drug, or an antiarrhythmic. The first thing a good CRO partner does is map your indication to the right disease model and the right readout, because a supplier that is excellent at atherosclerosis plaque work may have never run a pressure-overload heart failure study.

On the preclinical side, the in vivo menu is where cardiovascular gets specific. Heart failure programs commonly use transverse aortic constriction (TAC) for pressure overload, coronary ligation or ischemia-reperfusion for post-MI remodeling, and isoproterenol challenge for acute stress. Atherosclerosis work runs in ApoE-knockout or LDLR-knockout mice on a high-fat diet, with plaque burden and lesion histology as the readout. Antithrombotics need arterial and venous thrombosis models plus bleeding-time assays to show the therapeutic window. Hypertension and PAH programs use telemetered animals for continuous blood pressure, and right-heart catheterization for pulmonary pressures. Functional readouts like echocardiography (ejection fraction, fractional shortening), invasive pressure-volume loops, and cardiac biomarkers (NT-proBNP, troponin) carry the efficacy story.

Cardiac safety deserves its own line, because it is unusually central in this therapeutic area and it matters for every drug, not just cardiovascular ones. The hERG patch-clamp or automated ion-channel panel, in vivo QT studies in telemetered large animals, and increasingly the CiPA assays (multi-ion-channel plus stem-cell-derived cardiomyocyte work) sit at the front of the program. DMPK and bioanalytical round out preclinical the same way they do elsewhere. On the clinical side, cardiovascular is defined by scale: outcomes trials (CVOTs) measuring MACE often enroll thousands of patients across many countries and run for years, so you are buying clinical operations, an ECG and Holter core lab, a cardiac imaging core lab (echo and cardiac MRI), an independent clinical events committee for endpoint adjudication, biostatistics built for time-to-event analysis, and pharmacovigilance, frequently with a DSMB. Cardiac imaging core labs and event adjudication are two services that are nearly unique to how this area runs.

How do you choose a CRO for Cardiovascular?

The headline rate is the least useful number in front of you. In cardiovascular, the questions that actually predict a clean program are about whether the team has run your specific model or your specific endpoint before, with their own historical control data, rather than standing one up for the first time on your budget. Score two or three candidates against the same written scope so you are comparing like for like, and weight the items below over price.

  • Therapeutic-area and sub-indication experience: heart failure (HFrEF and HFpEF), hypertension, atherosclerosis and lipids, thrombosis, arrhythmia, PAH, and cardiomyopathy each behave differently. Ask for case studies in your exact sub-indication, not just "cardiovascular."
  • Relevant disease models or patient access: for preclinical, confirm the model (TAC, ischemia-reperfusion, ApoE/LDLR atherosclerosis, thrombosis, telemetered hypertension) is already validated in-house with reference data. For clinical, ask about site networks and cardiologist investigators in the geographies and patient population you need, because slow enrollment, not study conduct, is what sinks outcomes trials.
  • Cardiac safety capability: a validated hERG and ion-channel panel, in vivo telemetry for QT and blood pressure, and CiPA-aligned assays if your reviewers expect them. For the clinic, a centralized ECG and Holter core lab with the throughput your trial size demands.
  • Imaging and endpoint adjudication: a cardiac imaging core lab (echocardiography, cardiac MRI) with standardized acquisition and central reads, plus an independent clinical events committee for adjudicating MACE and other hard endpoints. These keep your primary endpoint defensible to the FDA and EMA.
  • Regulatory track record and data quality: a clean GLP record for the safety work, GCP-compliant systems and inspection history for the trial, CDISC-conformant data from day one, and biostatistics fluent in time-to-event and non-inferiority designs common to CVOTs.
  • Capacity and turnaround: a strong lab booked solid for months can be slower than a good lab with an open slot. Confirm real availability, report turnaround, and how change orders are priced when a study slips or a protocol amends, because in long cardiovascular trials amendments are close to inevitable.

Frequently asked questions

What preclinical models are used for cardiovascular drug development?
It depends on the indication. Heart failure programs use transverse aortic constriction (TAC) for pressure overload, coronary artery ligation or ischemia-reperfusion for post-MI remodeling, and isoproterenol for acute cardiac stress. Atherosclerosis runs in ApoE-knockout or LDLR-knockout mice on a high-fat diet. Antithrombotics use arterial and venous thrombosis models alongside bleeding-time assays. Hypertension and pulmonary arterial hypertension use telemetered animals for continuous pressure measurement and right-heart catheterization. Confirm the specific model you need is already validated in-house with historical control data before you sign, rather than having the CRO stand it up for the first time on your program.
Why is cardiac safety testing so important, even for non-cardiovascular drugs?
Drug-induced QT prolongation can cause a fatal arrhythmia (torsades de pointes), so regulators expect cardiac safety data on essentially every new drug, not only cardiovascular ones. The work centers on an in vitro hERG patch-clamp or automated ion-channel assay, an in vivo QT study in a telemetered large animal as part of the safety pharmacology core battery, and increasingly the CiPA assays, which combine multiple ion channels with stem-cell-derived cardiomyocytes. A clean cardiac safety package is one of the items reviewers check early, and a liability missed here is expensive to fix later.
What is a cardiovascular outcomes trial (CVOT) and what does it cost to run?
A CVOT is a large trial that measures hard clinical endpoints, typically major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction, stroke), rather than a surrogate like blood pressure or LDL. These trials often enroll thousands of patients across many countries and run for several years to accumulate enough events. Cost depends on event rate, sample size, duration, and geographies, so any flat number before a written scope is a guess. The largest line items are usually investigator grants and site pass-through costs, which can dwarf the CRO's direct fees, so ask for a unit-cost breakdown and a change-order policy before you compare bids.
Do I need a separate CRO for cardiac imaging and event adjudication?
Often yes, and it is normal in this area. A cardiac imaging core lab provides standardized acquisition protocols and central, blinded reads of echocardiography or cardiac MRI so that ejection fraction and similar endpoints stay comparable across every site. An independent clinical events committee adjudicates MACE and other hard endpoints so the primary analysis is defensible to the FDA and EMA. These are frequently specialist suppliers separate from your main clinical operations CRO. Through BioBridgeX you can source the imaging core lab, the events committee, the ECG core lab, and clin ops in one place, comparing quotes and contracting directly with each supplier you choose.
What endpoints and biomarkers matter most in cardiovascular trials?
It varies by indication. Heart failure leans on left ventricular ejection fraction, NT-proBNP, KCCQ quality-of-life scores, and the six-minute walk test, with hospitalization and cardiovascular death as hard endpoints. Lipid and atherosclerosis programs track LDL cholesterol and, ultimately, MACE. Hypertension uses ambulatory and office blood pressure. Pulmonary arterial hypertension uses pulmonary vascular resistance and the six-minute walk. Antithrombotics balance thrombotic event reduction against bleeding. Your biostatistics and data management suppliers should be fluent in the time-to-event and non-inferiority designs these endpoints usually require.
Is sourcing cardiovascular CRO and CDMO services on BioBridgeX free for buyers?
Yes. BioBridgeX is free for buyers and acts as the neutral marketplace, so it has no incentive to steer you toward a pricier lab. Suppliers pay a flat 2% platform fee. Because a cardiovascular program usually spans several specialists (a preclinical model CRO, a cardiac safety lab, an imaging core lab, an events committee, a clinical operations CRO), you can source all of them in one place, comparing quotes and contracting directly with each supplier you choose. Coverage runs across all indications and modalities, so the same account carries you from preclinical models through a full outcomes trial.

Source Cardiovascular work with one contract

Compare transparent quotes from qualified Cardiovascular CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes